Index

Note: Page numbers of article titles are in **boldface** type.

**A**

A Study of Cardiovascular Events in Diabetes (ASCEND) trial, 3, 10–11, 125–126
Acarbose, 146, 149
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, 45, 82, 143
Accountable care organizations, 164–165
A1c-Derived Average Glucose Study, 139
Actinin, genes for, 101
Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation study, 10
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 45, 82, 143
Acute kidney injury, in type 2 diabetes, 20
Adiponectin, in obesity, 67
ADVANCE study, 82, 143
Advanced glycation end products
   as drug targets, **115–134**
   formation of, 77, 116–117
AGTR1 gene, 94
Albuminuria, 1–2. See also Microalbuminuria.
   in type 2 diabetes, 8–11
   incidence of, 9–10
   obesity and, 65–66
   prevalence of, 8
   progression of, 9–10
   renal impairment without, 6–7
Aliskiren, 24, 41–42
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints
   (ALTITUDE) trial, 42
Allopurinol, 25, 129
Alpha-glucosidase inhibitors, 146, 149
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) trial, 42
Amylin mimetics, 147, 149
Angiotensin II type I receptor gene, 94
Angiotensin receptor blockers, 23–24, 38–42, 83–85
Angiotensin-converting enzyme inhibitors, 23–24, 38–42, 83–85
Angiotensin-converting enzymes, in hypertension, 34
Antifibrotic agents, 116–120
Antioxidant inflammation modulators, 120–123
ASCEND (A Study of Cardiovascular Events in Diabetes) trial, 3, 10–11, 125–126
AST-120, 119–120
Asymmetric dimethylarginine, in hypertension, 36
Atrasentan, 43–44, 125–126
AUH gene, 99–100
Australian Diabetes, Obesity, and Lifestyle study, 8
Avosentan, 25, 43–44, 123–126

B
Bardoxolone, 25, 120–123
BEACON (Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type Diabetes 2) study, 121
Benazepril, for hypertension, 40
BENEDICT (Bergamo Nephrologic Diabetes Complications Trial), 23
Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), 23
Biguanides, 145–146
Bile acid sequestrants, 147, 149
Bosentan, 43, 123
Bromocriptine, 147, 149

C
Candesartan, for hypertension, 40
Captopril, for hypertension, 38
Carnosinase 1 gene defects, 94
Casale Monferrato study, 8–10
China National Survey of Chronic Kidney Disease, 2–3
Chronic Disease Model, 164
Chronic Kidney Disease Epidemiology Collaboration formula, 1
Chronic Kidney Disease Prognosis Consortium, 9–10
Clinical decision support systems, 167
Clorpropamide, 145
CNCP1 gene defects, 94
Cohen diabetic rats, 54
COL28A1 gene, 102–103
Colesevelam, 147, 149
Collaborative care, for diabetic kidney disease, 157–173
  attitudes toward, 163
  barriers to, 158
  care delivery model for, 163–167
  diagnosis of, 158–161
  euglycemia and, 168
  glycemic control in, 167–168
  referral in, 161–163
  screening in, 158–161
Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy study, 39
Communication, in collaborative care, 166–167
Computerized provider order entry, 167
Cystatin C, 12–13
Cytokines, in obesity, 67

D
DCCT (Diabetes Control and Complications Trial), 5, 24, 139
DEMAND (Developing Education on MA for Awareness of renal and cardiovascular risk in Diabetes) study, 2–3, 11, 55
Diabetes Control and Complications Trial (DCCT), 5, 24, 139
Diabetes mellitus, in kidney disease, 135–156
Diabetes Mellitus Treatment for Renal Insufficiency Consortium, 20
Diabetic kidney disease
definition of, 1
economic burden of, 3
diagnosis of, 80
epidemiology of, 75–76
natural history of, 78–79
pathophysiology of, 76–80
treatment of, 80–86

EDIC (Epidemiology of Diabetes Interventions and Complications) study, 5–7, 24
Elderly individuals, diabetic kidney disease, 75–89
diagnosis of, 80
epidemiology of, 75–76
natural history of, 78–79
pathophysiology of, 76–80
treatment of, 80–86
ELMO1 gene, 98–100
Enalapril, for hypertension, 36
Endothelial cells, dysfunction of, in hypertension, 34, 36, 42–44
Endothelin, in hypertension, 36
Endothelin receptor blockers, 25, 123–126
End-stage renal disease
- causes of, 60
- epidemiology of, 3
- genetic factors in, 91–107
- in elderly individuals, 76
- in type 1 diabetes, 4, 6–7
- incidence of, 4, 6–7, 20
- mortality in, 6–7
- obesity and, 59–62

Engulfment and cell motility gene, 98–100

Epidemiology of Diabetes Interventions and Complications (EDIC) study, 5–7, 24

Estimated glomerular filtration rate, heritability of, 92–97

Ethnic factors, in diabetic kidney disease, 10–11, 91–107

Euglycemia, in collaborative care, 168

Exenatide, 147–148

Exercise, for diabetes mellitus, 144

F

Familial clustering, in diabetic kidney disease, 92–93

Family Investigation of Nephropathy and Diabetes (FIND) collection, 94

Fasidil, 129

FG-3019, 119

Fibrosis, inhibitors of, 116–120

FIND (Family Investigation of Nephropathy and Diabetes) collection, 94

Finnish Diabetes Register, 6–7

Free oxygen radicals, in hypertension, 36–37

Fructosamine, for glycemic control assessment, 140

G

Genetic factors, in diabetic kidney disease, 91–107
- familial clustering in, 92–93
- genome-wide association scans in, 98–101
- genome-wide linkage analysis in, 93–98
- next-generation sequencing in, 101–104

Genetics of Kidneys in Diabetes collections, 100

Genome-wide association scans, in diabetic kidney disease, 98–101

Genome-wide linkage analysis, in diabetic kidney disease, 93–98

Gliclazide, 146

Glimepiride, 145–146

Glipizide, 145–146

Glomerular filtration rate
- in early diabetes, 12–13
- in obesity, 63–64
- in prediabetes, 12

Glomerulonephritis, postinfectious, 21

Glomerulopathy
- age-related, 77
- in obesity, 63–64, 66–68

GLP-1 receptor agonists, 147–148
Gluconeogenesis, in kidney, 168
Glucose abnormalities, in kidney disease, 135–156
  glycemic control in, 138–150
  hypoglycemia, 143–144
  overview of, 136–138
Glyburide, 145–146
Glycated albumin, for glycemic control assessment, 140–141
Glycemic control, in kidney disease, 24, 81–82, 138–150
  challenges in, 144
  choices for, 150
  hypoglycemia in, 143–144
  in collaborative care, 167–168
  insulin for, 149–150
  noninsulin drugs for, 144–149
  testing for, 141–143
  value of, 138–141

H
  Hemodialysis, glycemic control in, 139–141
  Hemoglobin A1c measurement, 138–143
  Heritability, of diabetic kidney disease, 92–93
  Hyperfiltration
    in hypertension, 33–34
    in obesity, 63–64
  Hypertension, 31–51
    clinical context of, 32–33
    incidence of, 32–33
    obesity and, 64–65
    pathophysiology of, 33–37
    prevalence of, 32–33
    target treatment for, 32
    treatment of, 22–23, 38–45, 82–83
  Hypertension Optimal Treatment trial, 45
  Hypoglycemia, in diabetes mellitus treatment, 143–144

I
  IDNT (Irbesartan Diabetic Nephropathy Trial), 22, 45
  Inflammatory markers, in obesity, 67
  Insulin, for diabetes mellitus, 149–150
  Insulin resistance, in kidney disease, 135, 137
  Interleukin-6, in obesity, 67
  International Diabetes Federation Diabetes Atlas, on worldwide burden, 2
  Irbesartan, for hypertension, 41
  Irbesartan Diabetic Nephropathy Trial (IDNT), 22, 45

J
  Joslin Study of the Natural History of Microalbuminuria, 5, 7
  Joslin Study on the Genetics of type 2 Diabetes collection, 92–93
Index

K
Kaiser Permanente Northwest, cost statistics in, 3
Kaiser Permanente of Southern California, 161
KEEP (Kidney Early Evaluation Program), 76
Kidney Dialysis Outcomes Quality Initiative, 139–140, 158–159
Kidney disease
diabetic. See Diabetic kidney disease.
glucose abnormalities in, 135–156
Kidney Disease Outcomes Quality Initiative, 45
Kidney Early Evaluation Program (KEEP), 76, 159
Kimmelstiel-Wilson disease, 20
Kremezin Study Against Renal Diseases Progression in Korea (K-STAR), 120

L
Leptin, elevated, in obesity in, 67
Lifestyle changes, for diabetes mellitus, 144
Linagliptin, 147–148
Linkage analysis, in diabetic kidney disease, 93–98
Liraglutide, 147–148
Lisinopril, for hypertension, 40
Losartan, for hypertension, 41, 43

M
Matrix metalloproteinase inhibitors, 118–119
Meglitinides, 148–149
Metabolic syndrome, 21
Metformin, 145–146
Microalbuminuria, 1–2
in nonproteinuric diabetic kidney disease, 53–58
in type 1 diabetes, 3–8
in type 2 diabetes, 8–11
incidence of, 6
obesity and, 65–66
prevalence of, 5
progression of, 5, 7–8
Miglitol, 146, 149
Mineralocorticoid receptor antagonists, for hypertension, 39
Modification of Diet in Renal Disease Study equation, 1
Mortality
in end-stage renal disease, 6–7
in type 2 diabetes, 9
Multidisciplinary team, 165–166
MYH9 gene, 98
Myosin heavy chain 9 gene, 98

N
Nateglinide, 146, 149
National Health and Nutrition Examination Survey (NHANES), 55, 76
Index

National Institute of Diabetes and Digestive and Kidney Diseases study, 118

Nephrin
  genes for, 101
  in obesity, 67

Nephrologists, in collaborative care, 157–173

Nephropathy, diabetic. See Diabetic kidney disease.

Next-generation sequencing, in diabetic kidney disease, 101–104

NHANES (National Health and Nutrition Examination Survey), 55, 76

Nicorandil, for hypertension, 43

Nitric oxide, in hypertension, 36

Nonproteinuric diabetic kidney disease, 20–21, 53–58

O

Obesity, diabetic kidney disease and, 59–74
  epidemiology of, 60–62
  pathophysiology of, 62–68
  prevalence of, 59

ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial), 23, 39

Oxidative stress, in hypertension, 36–37

P

Palosuran, 128–129

Pancreas, transplantation of, 109–114

Paricalcitol, 126–128

Patient-centered medical home, 164–165

Pediatric patients, end-stage renal disease in, 20

Pentoxifylline, 120–121, 123

Phospholipase C, epsilon 1 gene, 101

Pioglitazone, 145–146, 148

Pirfenidone, 116, 118

Pittsburgh Epidemiology of Diabetes Complications Study, 6

Plasmacytoma variant translocation gene, 99–100

Podocin
  genes for, 101
  in obesity, 67

Pramlintide, 147, 149

Prediabetes, kidney function in, 12

PREDIAN (Pentoxifylline for Renoprotection in Diabetic Nephropathy) study, 123

PREVEND (Prevention of Renal and Vascular End state Disease), 65–66

Prevention of Renal and Vascular End state Disease (PREVEND), 65–66

Primary care providers, in collaborative care, 157–173

Proteinuria. See also Albuminuria; Microalbuminuria.
  diabetic kidney disease without, 20–21, 53–58
  in type 1 diabetes, 4–7
  incidence of, 4, 6
  natural history of, 5–8
  prevalence of, 5

PVT1 gene, 99–100
R
Ramipril Efficacy in Nephropathy (REIN) study, 42
Randomized Olmesartan And Diabetes Microalbuminuria Prevention (ROADMAP) study, 22–23
Receptor for AGE, 77
Referral, in collaborative care, 161–163
REIN (Ramipril Efficacy in Nephropathy) study, 42
RENAAL trial, 43
Renal Data System, 3
Renal Insufficiency and Cardiovascular Events study, 11–12
Renin inhibitors, for hypertension, 42
Renin-angiotensin system
  blockade of, 23–24, 38–42
  in hypertension, 34–35
  in obesity, 67–68
Repaglinide, 146, 149
Rho kinase inhibitors, 129
ROADMAP (Randomized Olmesartan And Diabetes Microalbuminuria Prevention) study, 22–23
Rosiglitazone, 145–146, 148
Rubosistaurin, 128

S
Saxagliptin, 147–148
Shanghai Diabetic Complications Study, 8
Single nucleotide polymorphisms, in diabetic kidney disease, 93–104
Sitagliptin, 147–148
Sodium
  reabsorption of, in hypertension, 33–34
  restriction of, for hypertension, 42
Spironolactone, for hypertension, 41
Steno Memorial Hospital study, 4–5, 7, 9
Sulfonylureas, 145–146
Sulodexide, 56
Swedish Linköping study, 6
Swedish National Diabetes Register, 11
Sympathetic nervous system, increased activity of, in hypertension, 36
Systolic Hypertension in the Elderly Population, 82–83

T
Telmisartan, for hypertension, 23, 39
Thiazolidinediones, 145–146, 148
Trandolapril, 23
Tranilast, 120
Transforming growth factor-β, 68, 94
Transient receptor potential cation channel subfamily C genes, 101
Transplantation, pancreas, for diabetic kidney disease, 109–114
Tubuloglomerular feedback, 63
Tumor necrosis factor-α, in obesity, 67
U
United Kingdom Prospective Diabetes Study (UKPDS), 9, 22, 24, 81–82, 95, 139
United States Renal Data System, 20
Uric acid control, 25

V
VA NEPHRON study, 39
Valsartan, for hypertension, 40
Veterans Affairs Diabetes Trial, 82, 143
VITAL study, 127
Vitamin D, for hypertension, 42

W
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 8